Therapeutic potential of boswellic acids: an update patent review (2016-2023).

IF 5.4 2区医学 Q1 CHEMISTRY, MEDICINAL

Expert Opinion on Therapeutic Patents Pub Date : 2024-08-01 Epub Date: 2024-07-05 DOI:10.1080/13543776.2024.2369626

Hidayat Hussain, Daijie Wang, Hesham R El-Seedi, Luay Rashan, Ishtiaq Ahmed, Muzaffar Abbas, Nilufar Z Mamadalieva, Haider N Sultani, Muhammad Iftikhar Hussain, Syed Tasadaque A Shah

{"title":"Therapeutic potential of boswellic acids: an update patent review (2016-2023).","authors":"Hidayat Hussain, Daijie Wang, Hesham R El-Seedi, Luay Rashan, Ishtiaq Ahmed, Muzaffar Abbas, Nilufar Z Mamadalieva, Haider N Sultani, Muhammad Iftikhar Hussain, Syed Tasadaque A Shah","doi":"10.1080/13543776.2024.2369626","DOIUrl":null,"url":null,"abstract":"Introduction: Boswellic acids (BAs) are a group of pentacyclic triterpenoids of the ursane and oleanane type. They have shown very interesting biological properties that have led to the development of a number of synthesis protocols. Both natural BAs and their synthetic derivatives may be useful in the treatment of a variety of cancers, viral infections and inflammatory diseases.Areas covered: This review covers patents relating to the therapeutic activities of natural BAs and their synthetic derivatives. The latest patented studies of boswellic acids (are summarized by using the keywords 'boswellic acid,' in SciFinder, PubMed, and Google Patents and databases in the year from 2016 to 2023.Expert opinion: Boswellic acids have shown potent antiviral, anticancer and anti-inflammatory potential. Few BAs analogues have been prepared by modification at the C24-CO2H functional groups. In particular, the C-24 amide and amino analogues have shown enhanced anticancer effects compared to the parent AKBA. In addition, BAs have the ability to form conjugates with other antiviral, anti-inflammatory and anticancer drugs that synergistically enhance their biological efficacy. In addition, this conjugation strategy will increase the solubility and bioavailability of BAs, which is one of the most important issues in the development of BAs.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"723-732"},"PeriodicalIF":5.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2024.2369626","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Boswellic acids (BAs) are a group of pentacyclic triterpenoids of the ursane and oleanane type. They have shown very interesting biological properties that have led to the development of a number of synthesis protocols. Both natural BAs and their synthetic derivatives may be useful in the treatment of a variety of cancers, viral infections and inflammatory diseases.

Areas covered: This review covers patents relating to the therapeutic activities of natural BAs and their synthetic derivatives. The latest patented studies of boswellic acids (are summarized by using the keywords 'boswellic acid,' in SciFinder, PubMed, and Google Patents and databases in the year from 2016 to 2023.

Expert opinion: Boswellic acids have shown potent antiviral, anticancer and anti-inflammatory potential. Few BAs analogues have been prepared by modification at the C24-CO₂H functional groups. In particular, the C-24 amide and amino analogues have shown enhanced anticancer effects compared to the parent AKBA. In addition, BAs have the ability to form conjugates with other antiviral, anti-inflammatory and anticancer drugs that synergistically enhance their biological efficacy. In addition, this conjugation strategy will increase the solubility and bioavailability of BAs, which is one of the most important issues in the development of BAs.

查看原文本刊更多论文

乳香酸的治疗潜力：最新专利综述（2016-2023 年）。

简介：乳香酸（BA）是一类乌苏烷和齐墩果烷类型的五环三萜类化合物。它们具有非常有趣的生物特性，并因此开发出了许多合成方案。天然 BA 及其合成衍生物可用于治疗各种癌症、病毒感染和炎症性疾病：本综述涉及与天然生物碱及其合成衍生物的治疗活性有关的专利。通过使用关键字 "乳香酸"，在SciFinder、PubMed、谷歌专利和数据库中汇总了2016年至2023年有关乳香酸的最新专利研究：乳香酸具有强大的抗病毒、抗癌和抗炎潜力。通过对 C24-CO2H 官能团进行修饰，制备出的乳香酸类似物为数不多。与 AKBA 母体相比，C-24 氨基和氨基类似物的抗癌效果尤其明显。此外，BA 还能与其他抗病毒、抗炎和抗癌药物形成共轭物，从而协同增强其生物功效。此外，这种共轭策略还能提高 BA 的溶解度和生物利用度，而这正是 BA 开发过程中最重要的问题之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Patents 医学-药学

CiteScore

12.10

自引率

1.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.